Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Mar 21, 2024
DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and full year 2023 financial results and provided a corporate update.
